TSIEX08:	Incidence and Reason for Dose Modification; Safety Analysis Set (Study jjcs - core)					
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	
Time Point 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	
  Dose Modification, n (%) 	N=53 	N=73 	N=126 	N=59 	
Overall 	53 	73 	126 	59 	
Dose not administered 	47 (88.7%) 	52 (71.2%) 	99 (78.6%) 	49 (83.1%) 	
Adverse Event 	1 (1.9%) 	0 	1 (0.8%) 	0 	
Other 	1 (1.9%) 	0 	1 (0.8%) 	0 	
Dose adjusted 	1 (1.9%) 	0 	1 (0.8%) 	0 	
Adverse Event 	1 (1.9%) 	0 	1 (0.8%) 	0 	
Other 	1 (1.9%) 	0 	1 (0.8%) 	0 	
 	 	 	 	 	
Baseline 	53 	73 	126 	59 	
Dose not administered 	28 (52.8%) 	36 (49.3%) 	64 (50.8%) 	24 (40.7%) 	
 	 	 	 	 	
Week 2 	53 	52 	105 	56 	
Dose not administered 	28 (52.8%) 	28 (53.8%) 	56 (53.3%) 	30 (53.6%) 	
Adverse Event 	1 (1.9%) 	0 	1 (1.0%) 	0 	
Dose adjusted 	1 (1.9%) 	0 	1 (1.0%) 	0 	
Adverse Event 	1 (1.9%) 	0 	1 (1.0%) 	0 	
 	 	 	 	 	
Week 24 	20 	15 	35 	40 	
Dose not administered 	9 (45.0%) 	8 (53.3%) 	17 (48.6%) 	25 (62.5%) 	
Adverse Event 	1 (5.0%) 	0 	1 (2.9%) 	0 	
Other 	1 (5.0%) 	0 	1 (2.9%) 	0 	
Dose adjusted 	1 (5.0%) 	0 	1 (2.9%) 	0 	
Adverse Event 	1 (5.0%) 	0 	1 (2.9%) 	0 	
Other 	1 (5.0%) 	0 	1 (2.9%) 	0 	

Note: Percentages are based on the number of subjects who had a visit at the specified time point. 	
Note: Percentages are based on the number of subjects who had a visit at the specified time point.	
Note: Percentages are based on the number of subjects who had a visit at the specified time point.	
Note: Percentages are based on the number of subjects who had a visit at the specified time point.	
Note: Percentages are based on the number of subjects who had a visit at the specified time point.	
Note: Subjects may be counted in more than one category. 	: Subjects may be counted in more than one category.	: Subjects may be counted in more than one category.	: Subjects may be counted in more than one category.	: Subjects may be counted in more than one category.